GlassScriptPhysician profile
Justin Vines
NPI 1295147932
$6,248.60
in general payments reported to CMS, 2019-2025
34 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $545 · 2021: $860 · 2022: $966 · 2023: $1,026 · 2024: $1,136 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,099.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.48 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $681.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $648.52 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $503.07 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $497.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.38 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $369.67 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $337.01 | 2020-2025 | |
| Amgen INC. | $334.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $301.03 | 2020-2022 | |
| Exact Sciences Corporation | $248.64 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.06 | 2021-2024 | Xifaxan |
| Corium, LLC | $133.43 | 2023 | Azstarys |
| Abbott Laboratories | $112.07 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $102.58 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $75.65 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $59.29 | 2021 | |
| Mylan Specialty L.P. | $46.68 | 2024 | Yupelri |
| Neurocrine Biosciences, INC. | $42.25 | 2024-2025 | Ingrezza |
| Astellas Pharma US INC | $39.24 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $38.10 | 2023 | Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $37.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.60 | 2019-2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $28.96 | 2025 | Rexulti |
| Tonix Medicines, INC. | $26.85 | 2025 | Tonmya |
| Genentech USA, INC. | $23.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.01 | 2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $21.56 | 2025 | Yupelri |
| Dexcom, INC. | $21.40 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.78 | 2023 | Inpen Smart Insulin Delivery System |
| Shire North American Group INC | $18.63 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2024 | Eliquis |
| Adlon Therapeutics L.P. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.